July, 2024
July 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
A comprehensive NGS test supporting decisions in blood cancers – Lucence
Jul 8, 2024, 04:44

A comprehensive NGS test supporting decisions in blood cancers – Lucence

Lucence shared a post on LinkedIn:

Swift Sensitive Surveillance. Because Cure Matters.

Proud to announce our new HemeMark service upgrade – now immediately available. HemeMark is a comprehensive NGS test supporting decisions in blood cancers.

Key features:

  • 72 genes (from 45 genes) and microsatellite instability (MSI) more useful actionable information guiding treatment decisions.
  • 0.05% VAF (from 0.1% VAF) for even greater sensitivity, powered by our proprietary mirror barcodes.
  • 2 weeks turnaround time
  • Run in our CAP-accredited and CLIA-licensed laboratory.

100% concordance of mutations in paired blood and bone marrow has been shown at >0.5% VAF threshold using HemeMark, and 86% at >0.1% threshold (Lim B et al, AACR 2023)

Product brochure.

For non-US physicians only.”

Min-Han Tan, Founding CEO of Lucence, shared this post, adding:

“Glad for this upgrade of HemeMark to support physicians caring for patients with leukemias and lymphomas.”

Sources: Lucence/LinkedIn and Min-Han Tan/LinkedIn                               .